ArticleEuropean urology open science2026
Large-scale Genomic Landscape and Clinical Outcomes of De Novo and Treatment-emergent Neuroendocrine Prostate Cancer.
Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Neuroendocrine prostate cancer (NEPC) is a rare, aggressive subtype of prostate cancer that arises either as de novo or as a treatment-emergent phenotype during androgen-deprivation therapy. Given its rarity, large-scale studies comparing genomic features and clinical outcomes between de novo NEPC and treatment-emergent NEPC (t-NEPC) are limited. We leveraged a nationwide comprehensive genomic profiling database to characterize the genomic landscape of NEPC and to describe the overall survival (OS) after initiation of NEPC treatment, with exploratory comparisons between de novo NEPC and t-NEPC. Design outcome measurements and statistical analysis: We retrospectively analyzed 302 patients with NEPC identified from among 5893 patients with prostate cancer registered in the Center for Cancer Genomics and Advanced Therapeutics database. Patients were classified as de novo NEPC ( Results and limitations: The most frequent genomic alterations in de novo NEPC and t-NEPC, respectively, were Conclusions: In this nationwide genomic analysis, de novo NEPC and t-NEPC showed largely similar genomic profiles after neuroendocrine differentiation; however, these findings should be interpreted with caution because of limitations in available clinical variables. These findings provide real-world insights into the clinical and genomic characteristics of NEPC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.